Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
Article Details
Authors
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi
Article Type
Corrigendum
DOI
10.7573/dic.2021-5-2
Related Articles
- Review of the experiences from the first childhood influenza vaccination programme with a live attenuated influenza vaccine in England and Scotland
- A non-pharmacological approach to the treatment of urinary tract infections: case reports with Utipro® Plus
- Kawasaki disease in siblings and a review of drug treatment
Article Page
AbstractThe authors wish to make the following corrections to their article:
Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1
Download free full text PDF
 in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study){kind=link}